SILO PHARMA INC (SILO) Stock Price, Forecast & Analysis
NASDAQ:SILO • US82711P2011
SILO Key Statistics, Chart & Performance
The current stock price of SILO is 0.383 USD. In the past month the price increased by 17.2%. In the past year, price decreased by -70.54%.
SILO Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to SILO. When comparing the yearly performance of all stocks, SILO is a bad performer in the overall market: 92.78% of all stocks are doing better.
SILO Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to SILO. No worries on liquidiy or solvency for SILO as it has an excellent financial health rating, but there are worries on the profitability.
SILO Financial Highlights
Over the last trailing twelve months SILO reported a non-GAAP Earnings per Share(EPS) of -0.93. The EPS increased by 21.56% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -79.51% | ||
| ROE | -101.36% | ||
| Debt/Equity | 0 |
SILO Forecast & Estimates
SILO Ownership
SILO Latest News, Press Relases and Analysis
SILO Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 16.1 | 414.026B | ||
| AMGN | AMGEN INC | 16.73 | 207.692B | ||
| GILD | GILEAD SCIENCES INC | 16.57 | 186.139B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.26 | 123.316B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.5 | 83.604B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 47.57 | 42.945B | ||
| INSM | INSMED INC | N/A | 31.206B | ||
| NTRA | NATERA INC | N/A | 28.37B | ||
| BIIB | BIOGEN INC | 12.1 | 27.598B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.69 | 22.521B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About SILO
Company Profile
Silo Pharma, Inc. is a developmental stage biopharmaceutical company, which engages in the merging of traditional therapeutics with psychedelic research. The company is headquartered in Sarasota, Florida. The company went IPO on 2012-01-05. The Company’s therapeutic focus is on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company’s portfolio includes programs, such as for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s disease and multiple sclerosis. Its lead product candidate, SPC-15, is designed as a novel serotonin 4 (5-HT4) receptor agonist that utilizes biomarkers for treatment of stress-induced psychiatric disorders such as PTSD and anxiety disorders. SPC-14 targets glutamate receptor NDMAR and serotonin 5-HT4 to address cognitive and neuropsychiatric symptoms in Alzheimer’s disease. SPU-16 is a candidate targeting central nervous system (CNS) disorders, with an initial indication for multiple sclerosis.
Company Info
SILO PHARMA INC
677 N Washington Blvd
Sarasota FLORIDA US
Employees: 3
Phone: 17184009031
SILO PHARMA INC / SILO FAQ
What does SILO do?
Silo Pharma, Inc. is a developmental stage biopharmaceutical company, which engages in the merging of traditional therapeutics with psychedelic research. The company is headquartered in Sarasota, Florida. The company went IPO on 2012-01-05. The Company’s therapeutic focus is on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company’s portfolio includes programs, such as for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s disease and multiple sclerosis. Its lead product candidate, SPC-15, is designed as a novel serotonin 4 (5-HT4) receptor agonist that utilizes biomarkers for treatment of stress-induced psychiatric disorders such as PTSD and anxiety disorders. SPC-14 targets glutamate receptor NDMAR and serotonin 5-HT4 to address cognitive and neuropsychiatric symptoms in Alzheimer’s disease. SPU-16 is a candidate targeting central nervous system (CNS) disorders, with an initial indication for multiple sclerosis.
What is the stock price of SILO PHARMA INC today?
The current stock price of SILO is 0.383 USD. The price increased by 7.4% in the last trading session.
What is the dividend status of SILO PHARMA INC?
SILO does not pay a dividend.
What is the ChartMill technical and fundamental rating of SILO stock?
SILO has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the growth outlook for SILO PHARMA INC?
The Revenue of SILO PHARMA INC (SILO) is expected to decline by 0% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the market cap for SILO PHARMA INC?
SILO PHARMA INC (SILO) has a market capitalization of 5.10M USD. This makes SILO a Nano Cap stock.
What is the ownership structure of SILO PHARMA INC (SILO)?
You can find the ownership structure of SILO PHARMA INC (SILO) on the Ownership tab.